Efficacy and Prolonged Safety of Haemophilus influenzae Type b Conjugate Vaccines


Citar

Texto integral

Resumo

Objective::The purpose of this study was to find data proving the influence of the Haemophilus influenzae type b (Hib) conjugate vaccination on the frequency of invasive Hib illness.

Methodology::A systematic literature search was conducted on the PubMed database to identify peerreviewed publications pertaining to the epidemiology of Haemophilus influenzae meningitis, both before and after the introduction of Haemophilus influenzae type b (Hib) conjugate vaccines. The search query employed a combination of relevant keywords, including \"invasive,\" \"Haemophilus,\" \"influenzae,\" \"meningitis,\" and specific serotype b (Hib). Additionally, terms related to epidemiology, burden, risk factors, impact, Hib vaccine, Hib conjugate vaccine, combination vaccine, vaccine production, efficacy, immunisation coverage, surveillance, review, clinical aspects, outcomes, and various age groups (adults and children) were incorporated.

Result::The search encompassed articles published till now. Subsequently, relevant research papers concerning Haemophilus influenzae meningitis were subjected to a comprehensive review and analysis.

Conclusion::The Hib conjugate vaccination has shown to be extremely effective when administered to the entire population. However, changes to the immunisation protocol appear to be required in order to effectively manage invasive Hib illness.

Sobre autores

Nishita Tripathi

Amity Institute of Biotechnology, Amity University Uttar Pradesh Lucknow Campus

Email: info@benthamscience.net

Sayali Mukherjee

Amity Institute of Biotechnology, Amity University Uttar Pradesh Lucknow Campus

Autor responsável pela correspondência
Email: info@benthamscience.net

Bibliografia

  1. Khattak ZE, Anjum F. Haemophilus influenzae infection.In: StatPearls. Treasure Island, FL: StatPearls Publishing 2023. https://www.ncbi.nlm.nih.gov/books/NBK562176/ Updated 2023 Apr 27 Internet
  2. Arístegui J, Usonis V, Coovadia H, et al. Facilitating the who expanded program of immunization: the clinical profile of a combined diphtheria, tetanus, pertussis, hepatitis b and Haemophilus influenzae type b vaccine. Int J Infect Dis 2003; 7(2): 143-51. doi: 10.1016/S1201-9712(03)90011-7 PMID: 12839717
  3. Mallet E, Belohradsky BH, Lagos R, et al. A liquid hexavalent combined vaccine against diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae type B and hepatitis B: review of immunogenicity and safety. Vaccine 2004; 22(11-12): 1343-57. doi: 10.1016/j.vaccine.2003.09.039 PMID: 15063556
  4. Levine OS, Ortiz E, Contreras R, et al. Cost-benefit analysis for the use of Haemophilus influenzae type b conjugate vaccine in Santiago, Chile. Am J Epidemiol 1993; 137(11): 1221-8. doi: 10.1093/oxfordjournals.aje.a116624 PMID: 8322763
  5. Lagos R, Levine OS, Avendaño A, Horwitz I, Levine MM. The introduction of routine Haemophilus influenzae type b conjugate vaccine in Chile: a framework for evaluating new vaccines in newly industrializing countries. Pediatr Infect Dis J 1998; 17(9) (Suppl.): S139-48. doi: 10.1097/00006454-199809001-00010 PMID: 9781748
  6. Mahoney R. Policy analysis: An essential research tool for the introduction of vaccines in developing countries. J Health Popul Nutr 2004; 22(3): 331-7. PMID: 15609786
  7. Watt JP, Levine OS, Santosham M. Global reduction of Hib disease: what are the next steps? Proceedings of the meeting Scottsdale, Arizona, September 22-25, 2002. J Pediatr 2003; 143(6) (Suppl.): S163-87. doi: 10.1067/S0022-3476(03)00576-6 PMID: 14657805
  8. Ulanova Marina . Global epidemiology of invasive Haemophilus influenzae type a disease: Do we need a new vaccine? J Vaccines 2013; Article ID 941461. 14 pages, 2013 doi: 10.1155/2013/941461
  9. World Health Organization.Estimating the local burden of Haemophilus influenzae type b Hib disease preventable by vaccination. Geneva: WHO 2001. WHO/V&B/01.27
  10. Di Fabio JL, de Quadros C. Considerations for combination vaccine development and use in the developing world. Clin Infect Dis 2001; 33(s4) (Suppl. 4): S340-5. doi: 10.1086/322571 PMID: 11709770
  11. World Health Organization Countries using Hib vaccine in their national infant immunization system as of December 2003.
  12. Levine OS, Schwartz B, Pierce N, Kane M. Development, evaluation and implementation of Haemophilus influenzae type b vaccines for young children in developing countries: current status and priority actions. Pediatr Infect Dis J 1998; 17(9) (Suppl.): S95-S113. doi: 10.1097/00006454-199809001-00003 PMID: 9781741
  13. Feikin DR, Nelson CB, Watt JP, Mohsni E, Wenger JD, Levine OS. Rapid assessment tool for Haemophilus influenzae type b disease in developing countries. Emerg Infect Dis 2004; 10(7): 1270-6. doi: 10.3201/eid1007.030737 PMID: 15324548
  14. Peltola H. Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. Clin Microbiol Rev 2000; 13(2): 302-17. doi: 10.1128/CMR.13.2.302 PMID: 10756001
  15. Peltola H. Spectrum and burden of severe Haemophilus influenzae type b diseases in Asia. Bull World Health Organ 1999; 77(11): 878-87. PMID: 10612883
  16. Gessner B. Worldwide variation in the incidence of Haemophilus influenzae type b meningitis and its association with ampicillin resistance. Eur J Clin Microbiol Infect Dis 2002; 21(2): 79-87. doi: 10.1007/s10096-001-0667-z PMID: 11939404
  17. Kim J, Jang YT, Kim JD, et al. Incidence of Haemophilus influenzae type b and other invasive diseases in South Korean children. Vaccine 2004; 22(29-30): 3952-62. doi: 10.1016/j.vaccine.2004.04.003 PMID: 15364444
  18. Saha SK, Baqui AH, Darmstadt GL, et al. Invasive Haemophilus influenzae type b diseases in Bangladesh, with increased resistance to antibiotics. J Pediatr 2005; 146(2): 227-33. doi: 10.1016/j.jpeds.2004.09.007 PMID: 15689914
  19. Gessner BD, Sutanto A, Linehan M, et al. Incidences of vaccine-preventable Haemophilus influenzae type b pneumonia and meningitis in Indonesian children: Hamlet-randomised vaccine-probe trial. Lancet 2005; 365(9453): 43-52. doi: 10.1016/S0140-6736(04)17664-2 PMID: 15643700
  20. Lagos R, Horwitz I, Toro J, et al. Large scale, postlicensure, selective vaccination of Chilean infants with PRP-T conjugate vaccine: Practicality and effectiveness in preventing invasive Haemophilus influenzae type b infections. Pediatr Infect Dis J 1996; 15(3): 216-22. doi: 10.1097/00006454-199603000-00008 PMID: 8852909
  21. Weiss DPL, Coplan P, Guess H. Epidemiology of bacterial meningitis among children in Brazil, 1997-1998. Rev Saude Publica 2001; 35(3): 249-55. doi: 10.1590/S0034-89102001000300006 PMID: 11486147
  22. Simões LL, Andrade AL, Laval CA, et al. Impact of Haemophilus influenzae b (Hib) vaccination on meningitis in Central Brazil Rev Saude Publica 2004; 38(5): 664-70. PMID: 15499437
  23. Gilsdorf JR. Hib vaccines: Their impact on Haemophilus influenzae type b disease. J Infect Dis 2021; 224(12) (Suppl. 4): S321-30. doi: 10.1093/infdis/jiaa537 PMID: 34590133
  24. Kelly DF, Moxon ER, Pollard AJ. Haemophilus influenzae type b conjugate vaccines. Immunology 2004; 113(2): 163-74. doi: 10.1111/j.1365-2567.2004.01971.x PMID: 15379976
  25. Gomez PL, Robinson JM. Vaccine manufacturing. Plotkin’s Vaccines 2018; 51-60.e1. doi: 10.1016/B978-0-323-35761-6.00005-5
  26. Hibtiter (diphtheria CRM197 protein conjugate): Uses, dosage, side effects, interactions, warning. RxList. https://www.rxlist.com/hibtiter-drug.htm#description Last updated on RxList: 10/12/2022
  27. https://www.rxlist.com/acthib-drug.htm ActHIB (haemophilus B conjugate vaccine): Uses, dosage, side effects, interactions, warning. RxList.
  28. https://www.rxlist.com/pedvaxhib-drug.htm Pedvax Hib (haemophilus B conjugate vaccine): Uses, dosage, side effects, interactions, warning. RxList.
  29. Briere EC. Food and Drug Administration Approval for Use of Hiberix as a 3-Dose Primary Haemophilus influenzae Type b (Hib) Vaccination Series. MMWR Morb Mortal Wkly Rep 2016; 65(16): 418-9. doi: 10.15585/mmwr.mm6516a3 PMID: 27124887
  30. World Health Organization. In: Inspection report for WHO. Geneva, Switzerland 2019.
  31. https://www.rxlist.com/pentacel-drug.htm Pentacel (tetanus toxoid conjugate): Uses, dosage, side effects, interactions, warning. RxList.
  32. Oliver SE, Moore KL. Licensure of a diphtheria and tetanus toxoids and acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b conjugate, and hepatitis b vaccine, and guidance for use in infants. MMWR Morb Mortal Wkly Rep 2020; 69(5): 136-9. doi: 10.15585/mmwr.mm6905a5 PMID: 32027629
  33. Perry CM. Meningococcal groups C and Y and haemophilus B tetanus toxoid conjugate vaccine (HibMenCY-TT; MenHibrix(®)): a review. Drugs 2013; 73(7): 703-13. doi: 10.1007/s40265-013-0048-9 PMID: 23649970
  34. https://www.rxlist.com/comvax-drug.htm Comvax (haemophilus b conjugate and hepatitis B vaccine): Uses, dosage, side effects, interactions, warning. RxList.
  35. https://www.rxlist.com/pediarix-drug.htm Pediarix (diphtheria, tetanus Toxoids and acellular pertussis adsorbed, hepatitis B and inactivated poliovirus vaccine): Uses, dosage, side effects, interactions, warning. RxList.
  36. Easyfive-TT 2023. WHO - Prequalification of Medical Products (IVDs, Medicines, Vaccines and Immunization Devices, Vector Control).
  37. Aloysia D’Cor N, Siddaiah P, Mohapatra S, et al. Safety and immunogenicity of a new formulation of a pentavalent DTwP-HepB-Hib vaccine in healthy Indian infants-A randomized study. PLoS One 2023; 18(8)e0284898 doi: 10.1371/journal.pone.0284898 PMID: 37582114
  38. Serum Institute of India - poliovac (PFS/SD) - poliomyelitis vaccine (inactivated) I.P. (n.d.-a). https://www.seruminstitute.com/product_ind_pentavac.php (Last accessed September 2023)
  39. Kummeling I, Thijs C, Stelma F, Huber M, van den Brandt PA, Dagnelie PC. Diphtheria, pertussis, poliomyelitis, tetanus, and Haemophilus influenzae type b vaccinations and risk of eczema and recurrent wheeze in the first year of life: The KOALA Birth Cohort Study. Pediatrics 2007; 119(2): e367-73. doi: 10.1542/peds.2006-1479 PMID: 17272598
  40. Centre for Disease Control and Prevention (CDC). Chapter 2 In: Haemophilus influenzae invasive disease In: Manual for the surveillance of vaccine preventable diseases. National Center for Immunization and Respiratory Diseases 2019.
  41. Griffiths UK, Clark A, Gessner B, et al. Dose-specific efficacy of Haemophilus influenzae type b conjugate vaccines: A systematic review and meta-analysis of controlled clinical trials. Epidemiol Infect 2012; 140(8): 1343-55. doi: 10.1017/S0950268812000957 PMID: 22583474
  42. Slack M, Esposito S, Haas H, et al. Haemophilus influenzae type b disease in the era of conjugate vaccines: Critical factors for successful eradication. Expert Rev Vaccines 2020; 19(10): 903-17. doi: 10.1080/14760584.2020.1825948 PMID: 32962476
  43. Zhang H, Garcia C, Yu W, et al. National and provincial impact and cost-effectiveness of Haemophilus influenzae type b conjugate vaccine in China: A modeling analysis. BMC Med 2021; 19(1): 181. doi: 10.1186/s12916-021-02049-7 PMID: 34376214
  44. Rodrigues CMC, Plotkin SA. Impact of vaccines; health, economic and social perspectives. Front Microbiol 2020; 11: 1526. doi: 10.3389/fmicb.2020.01526 PMID: 32760367
  45. Slack MPE. Long term impact of conjugate vaccines on Haemophilus influenzae meningitis: Narrative review. Microorganisms 2021; 9(5): 886. doi: 10.3390/microorganisms9050886 PMID: 33919149
  46. Collins S, Ramsay M, Campbell H, Slack MPE, Ladhani SN. Invasive Haemophilus influenzae type b disease in England and Wales: Who is at risk after 2 decades of routine childhood vaccination? Clin Infect Dis 2013; 57(12): 1715-21. doi: 10.1093/cid/cit579 PMID: 24076970
  47. Laval CAB, Pimenta FC, Andrade JG, Andrade SS, Andrade ALSS. Progress towards meningitis prevention in the conjugate vaccines era. Braz J Infect Dis 2003; 7(5): 315-24. doi: 10.1590/S1413-86702003000500006 PMID: 14552741
  48. Ruocco G, Curto S, Savio M, Laurani H, Frocht R. Vacunación contra Haemophilus influenzae tipo b en el Uruguay: Experiencia e impacto. Rev Panam Salud Publica 1999; 5(3): 197-9. doi: 10.1590/S1020-49891999000300021 PMID: 10355316
  49. Nascimento-Carvalho CM, de Andrade AL. Haemophilus influenzae type b vaccination: long-term protection. J Pediatr 2006; 82(3) (Suppl.): S109-14. doi: 10.1590/S0021-75572006000400013 PMID: 16826309
  50. Agudelo CI, Muñoz N, De la Hoz F. Rapid assessment of the impact of Haemophilus influenzae vaccine serotype b in Colombia Rev Panam Salud Publica 2000; 8(3): 181-4. doi: 10.1590/S1020-49892000000800005 PMID: 11036428
  51. Freitas H. Meningite por Haemophilus influenzae b no Distrito Federal Aspectos epidemiológicos e impacto após introdução da vacina dissertação. In: Brasília: Universidade de Brasília. 2000.
  52. Takemura NS, Andrade SM. Haemophilus influenzae type b meningitis in the state of Paraná, Brazil. J Pediatr 2001; 77(5): 387-92. doi: 10.2223/JPED.280 PMID: 14647843
  53. Dickinson FO, Pérez AE, Galindo MA, Quintana I. Impacto de la vacunación contra Haemophilus influenzae tipo b en Cuba. Rev Panam Salud Publica 2001; 10(3): 169-73. doi: 10.1590/S1020-49892001000900004 PMID: 11702372
  54. Díaz PJM, Catalán NL, Urrutia LMT, et al. Tendencias en la etiología de la meningitis bacteriana aguda en niños chilenos, período 1989-1998.: Impacto de la vacuna anti-H influenzae tipo b (Hib). Rev Med Chil 2001; 129(7): 719-26. doi: 10.4067/S0034-98872001000700003 PMID: 11552439
  55. Ribeiro GS, Reis JN, Cordeiro SM, et al. Prevention of Haemophilus influenzae type b (Hib) meningitis and emergence of serotype replacement with type a strains after introduction of Hib immunization in Brazil. J Infect Dis 2003; 187(1): 109-16. doi: 10.1086/345863 PMID: 12508153
  56. Kmetzsch CI, Schermann MT, Santana JCB, et al. Occurrence of Haemophylus influenzae B meningitis after the implementation of a mass vaccination program. J Pediatr 2003; 79(6): 530-6. doi: 10.2223/JPED.1114 PMID: 14685451
  57. Delahoz F, Higuera AB, Di Fabio JL, et al. Effectiveness of Haemophilus influenzae type b vaccination against bacterial pneumonia in Colombia. Vaccine 2004; 23(1): 36-42. doi: 10.1016/j.vaccine.2004.05.017 PMID: 15519705
  58. Review panel on Haemophilus influenzae type b (Hib) disease burden in Bangladesh, Indonesia and other Asian countries, Bangkok, 28-29 January 2004. Wkly Epidemiol Rec 2004; 79(18): 173-5. PMID: 15168565
  59. Nelson CM, Sutanto A, Gessner BD, Suradana IG, Steinhoff MC, Arjoso S. Age- and cause-specific childhood mortality in Lombok, Indonesia, as a factor for determining the appropriateness of introducing Haemophilus influenzae type b and pneumococcal vaccines. J Health Popul Nutr 2000; 18(3): 131-8. PMID: 11262765
  60. Jones G, Steketee RW, Black RE, Bhutta ZA, Morris SS. How many child deaths can we prevent this year? Lancet 2003; 362(9377): 65-71. doi: 10.1016/S0140-6736(03)13811-1 PMID: 12853204
  61. Andrade ALSS, Afonso ET, Silva SA, Neto OLM, Marques SM, Martelli CMT. Invasive Disease-related mortality among children before and after the introduction of the Haemophilus influenzae type B conjugate vaccine in Brazil. Int J Infect Dis 2004; 8 (Suppl. 1): 75.
  62. Garner D, Weston V. Effectiveness of vaccination for Haemophilus influenzae type b. Lancet 2003; 361(9355): 395-6. doi: 10.1016/S0140-6736(03)12385-9 PMID: 12573380
  63. Trotter CL, Ramsay ME, Slack MP. Rising incidence of Haemophilus influenzae type b disease in England and Wales indicates a need for a second catch-up vaccination campaign. Commun Dis Public Health 2003; 6(1): 55-8. PMID: 12736974
  64. van Alphen L, Spanjaard L, van der Ende A, Schuurman I, Dankert J. Effect of nationwide vaccination of 3-month-old infants in The Netherlands with conjugate Haemophilus influenzae type b vaccine: High efficacy and lack of herd immunity. J Pediatr 1997; 131(6): 869-73. doi: 10.1016/S0022-3476(97)70035-0 PMID: 9427892
  65. Rijkers GT, Vermeer-de Bondt PE, Spanjaard L, Breukels MA, Sanders EAM. Return of Haemophilus influenzae type b infections. Lancet 2003; 361(9368): 1563-4. doi: 10.1016/S0140-6736(03)13201-1 PMID: 12737898
  66. Ramsay ME, McVernon J, Andrews NJ, Heath PT, Slack MP. Estimating Haemophilus influenzae type b vaccine effectiveness in England and Wales by use of the screening method. J Infect Dis 2003; 188(4): 481-5. doi: 10.1086/376997 PMID: 12898433
  67. Trotter CL, McVernon J, Andrews NJ, Burrage M, Ramsay ME. Antibody to Haemophilus influenzae type b after routine and catch-up vaccination. Lancet 2003; 361(9368): 1523-4. doi: 10.1016/S0140-6736(03)13172-8 PMID: 12737867
  68. McVernon J, Andrews N, Slack MPE, Ramsay ME. Risk of vaccine failure after Haemophilus influenzae type b (Hib) combination vaccines with acellular pertussis. Lancet 2003; 361(9368): 1521-3. doi: 10.1016/S0140-6736(03)13171-6 PMID: 12737866
  69. Sarangi J, Cartwright K, Stuart J, Brookes S, Morris R, Slack M. Invasive Haemophilus influenzae disease in adults. Epidemiol Infect 2000; 124(3): 441-7. doi: 10.1017/S0950268899003611 PMID: 10982068
  70. McVernon J, Trotter CL, Slack MPE, Ramsay ME. Trends in Haemophilus influenzae type b infections in adults in England and Wales: Surveillance study. BMJ 2004; 329(7467): 655-8. doi: 10.1136/bmj.329.7467.655 PMID: 15374916
  71. Käyhty R, Peltola H, Karanko V, Mäkelä PH. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis 1983; 147(6): 1100. doi: 10.1093/infdis/147.6.1100 PMID: 6602191
  72. Heath PT, Booy R, Azzopardi HJ, et al. Antibody concentration and clinical protection after Hib conjugate vaccination in the United Kingdom. JAMA 2000; 284(18): 2334-40. doi: 10.1001/jama.284.18.2334 PMID: 11066183
  73. Barbour ML, Mayon-White RT, Coles C, Crook DWM, Moxon ER. The impact of conjugate vaccine on carriage of Haemophilus influenzae type b. J Infect Dis 1995; 171(1): 93-8. doi: 10.1093/infdis/171.1.93 PMID: 7798687
  74. McVernon J, Mitchison NA, Moxon ER. T helper cells and efficacy of Haemophilus influenzae type b conjugate vaccination. Lancet Infect Dis 2004; 4(1): 40-3. doi: 10.1016/S1473-3099(03)00859-4 PMID: 14720567
  75. Eskola J, Ward J, Dagan R, Goldblatt D, Zepp F, Siegrist CA. Combined vaccination of Haemophilus influenzae type b conjugate and diphtheria-tetanus-pertussis containing acellular pertussis. Lancet 1999; 354(9195): 2063-8. doi: 10.1016/S0140-6736(99)04377-9 PMID: 10636384
  76. Fitzgerald M, Canny M, O’Flanagan D. Vaccination catch-up campaign in response to recent increase in Hib infection in Ireland. Euro Surveill 2005; 10(9)E050929.2 PMID: 16788239
  77. American academy of pediatrics. Recommended childhood and adolescent immunization schedule United States In: Pickering LK, editor 2003 red book: . report of the Committee on Infectious Diseases 26th ed Elk Grove Village: American Academy of Pediatrics; 2003; p. 24.
  78. World Health Organization (n.d.). Immunization coverage https://www.who.int/news-room/fact-sheets/detail/immunization-coverage Global immunization coverage 2022 Geneva
  79. Wahl B, O’Brien KL, Greenbaum A, et al. Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: Global, regional, and national estimates for 2000–15. Lancet Glob Health 2018; 6(7): e744-57. doi: 10.1016/S2214-109X(18)30247-X PMID: 29903376
  80. Statista (2023) India: Share of Hib3 immunization coverage 2022.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bentham Science Publishers, 2024